CSIMarket
 
Inovio Pharmaceuticals Inc   (INO)
Other Ticker:  
 
 
Price: $10.7350 $-0.08 -0.694%
Day's High: $11.3 Week Perf: -10.84 %
Day's Low: $ 10.61 30 Day Perf: 46.25 %
Volume (M): 312 52 Wk High: $ 13.20
Volume (M$): $ 3,351 52 Wk Avg: $6.76
Open: $10.79 52 Wk Low: $3.89



 Market Capitalization (Millions $) 238
 Shares Outstanding (Millions) 22
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -135
 Cash Flow (TTM) (Millions $) -32
 Capital Exp. (TTM) (Millions $) 0

Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of DNA immunotherapies to treat and prevent infectious diseases, cancer, and other medical conditions. The company's innovative platform, called SynCon, allows for the rapid design and production of DNA-based vaccines and immune therapies. Inovio's technology aims to stimulate the body's immune system to target specific diseases, potentially providing safer and more effective treatment options.

Inovio has a diverse pipeline of product candidates in various stages of development, including treatments for HPV-related cancers, hepatitis B, HIV, and Zika virus, among others. The company has also recently gained attention for its efforts in developing a COVID-19 vaccine candidate, which has shown promising results in preclinical studies.

In addition to its research and development activities, Inovio has collaborations and partnerships with various organizations, including academic institutions, biopharmaceutical companies, and government agencies, to further advance its technology and expand its product portfolio.

Overall, Inovio Pharmaceuticals Inc is committed to leveraging its innovative DNA-based platform to address unmet medical needs and improve patient outcomes in the field of immunotherapy.


   Company Address: 660 W. Germantown Pike Plymouth Meeting 19462 PA
   Company Phone Number: 440-4200   Stock Exchange / Ticker: NASDAQ INO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc Reports Soft Business Performance in Fiscal Fourth Quarter of 2023

As a financial analyst and writer for the , I have been closely monitoring the recent financial results of Inovio Pharmaceuticals Inc, a prominent player in the Medical Equipment & Supplies sector. The company's performance in the October to December 31, 2023 time-frame has displayed both positive and concerning signs.
One aspect that stands out is Inovio Pharmaceuticals' ability to trim its losses significantly in comparison to the previous year. Despite facing vanishing revenues, the company achieved a substantial decrease in its shortfall per share. In the reporting season a year prior, the company experienced an EPS of $-2.25, while in the current period, it has managed to reduce the shortfall to $-1.03 per share.

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc Faces Astonishing Deficit of $-0.13 per Share in Explosive Fiscal Year-End Report for 2023

Inovio Pharmaceuticals Inc - A Bullish Outlook Despite Recent Setbacks
In the midst of challenging times for the Medical Equipment & Supplies industry, Inovio Pharmaceuticals Inc has managed to showcase its resilience and potential for growth. The company's recent financial report, covering the fiscal time-frame ending September 30, 2023, reveals some notable improvements compared to the same period a year ago.
While it is true that the company incurred a loss of $-0.13 per share, this figure demonstrates an improvement from the previous year's loss of $-0.15 per share. Moreover, it is worth noting that the loss remained consistent with the prior quarter. This stability in performance suggests that the company has managed to maintain a steady footing despite the challenges faced by the industry.

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc Shows Remarkable Financial Improvement in Q2 2023 Despite Stock Decline


Date: INSERT DATE
Inovio Pharmaceuticals Inc (NASDAQ: INO) has reported positive developments during the second quarter of the 2023 earnings season, as the company managed to significantly reduce losses per share compared to the previous year. Additionally, Inovio's income per share showed improvement when compared to the prior reporting season. However, these achievements were overshadowed by the stock's recent performance, which has seen a decline of -70.99% year-to-date.
During the second quarter of 2023, Inovio Pharmaceuticals reported a loss per share of $-0.13, a substantial decrease from the $-0.46 recorded a year ago. The company's income per share also showed improvement, rising from $-0.16 during the prior reporting season. These positive shifts can be attributed to a revenue jump of 45.805%, reaching $2.39 million from $1.64 million in the same reporting period the previous year. Additionally, sequential revenue experienced a modest increase of 3.104% from $2.32 million.
In comparison to its industry counterparts, Inovio Pharmaceuticals appears to have outperformed on the top-line, with the Medical Equipment & Supplies industry reporting only a 3.90% revenue rise during the same period. Despite these notable achievements, it is important to scrutinize the company's recent stock performance for a more holistic understanding of its investment potential.

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc: Record Revenue Surge Amidst Net Deficit, Investors Beware

Investing in the stock market always carries risks, and it's important for people to be cautious and do their research before making any decisions. In particular, the news coming out of Inovio Pharmaceuticals Inc may give investors pause.
While the company saw a strong surge in revenue in the fiscal first quarter of 2023, with a 33.564% increase to $2.32 million from the same period a year ago, it's worth noting that the company also reported a net deficit of $-40.649 million. This is a significant loss, even if it's an improvement over the $-106.948 million deficit reported in the same period a year ago.






 

Inovio Pharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Inovio Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Inovio Pharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com